TheraRadar
Landscape / Oncology
Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

AML Clinical Trial Landscape

Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow, affecting people of all ages. It is characterized by the rapid growth of abnormal white blood cells in the bone marrow, which interferes with the production of normal blood cells.

The AML clinical trial landscape is robust, with 1,765 trials registered since 2008. Currently, 678 trials are actively recruiting, enrolling, or active but not recruiting patients.

The majority of active trials are in early phases of development, with 350 in Phase 1 and 372 in Phase 2. Phase 3 trials account for 75 active trials, while Phase 4 trials are less common, with only 7 currently active.

AbbVie leads industry sponsorship of active trials with 6, followed by Taiho Oncology, Inc. with 5, Kura Oncology, Inc. with 4, and Orca Biosystems, Inc. and Ryvu Therapeutics SA each sponsoring 3 active trials. The high volume of Phase 1 and 2 trials suggests a strong focus on novel therapeutic approaches and early-stage drug development in AML.

Trial activity

703 active / 1,803 total since 2008
Active by phase 79 Ph3 / 169 371 Ph2 / 935 245 Ph1 / 685 8 Ph4 / 14

Competitive Intelligence

This AML competitive landscape maps 12 companies against 7 mechanisms of action (MOA) across 16 active drug-development programs. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in AML, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 12 companies 7 mechanisms 16 programs mapped 8 lowTrust (50%) ⏰ 1 due ≤6 mo click any cell → asset tearsheet
At a glance

Acute Myeloid Leukemia (AML) shows 16 programs across 12 companies and 7 mechanisms. The most contested mechanism is FLT3 (6 programs).

Key findings
  • 88% of BCL-2 programs (14 of 16) are combos with novel agents — class-extension work, not class-validation.
  • Top 3 mechanisms (BCL-2, BCL-2 inhibitor, DNA (cytosine-5)-methyltransferase 3A inhibitor) account for ~41% of programs — class concentration is moderate.
  • Ascentage Pharma Group runs 3 programs — the deepest pipeline in this view.
  • AB Science has the highest composite score (87) — most-imminent / most-advanced asset weighted higher than program count.
  • 9 hot readouts in next 6 months — most imminent: Kura Oncology (MENIN).
  • 26 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
  • 19 single-program mechanisms in the long tail — 5 are Ph2+ first-in-class first-mover bets.
  • 11 NME candidates in the long tail.
  • Most-novel-of-novel: Hutchmed IDH1 (Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 1 due ≤6 mo

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.
Unverified (lowTrust) cells:
Ph1 Ph2 Ph3 Ph4 ⚠ lowTrust +combo
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
FLT3
BCL-2
MENIN
BCL-2 inhibitor
DNA (cytosine-5)-methyltransferas…
Macrophage colony stimulating fac…
CD123
🇨🇳Ascentage Pharma Group
Daiichi Sankyo
Johnson & Johnson
Kura Oncology
AbbVie
Bristol-Myers Squibb
Lomond Therapeutics Holdings
Shijiazhuang Yiling
Syndax
Tarapeutics Science
Bio-Path Holdings
Chongqing Precision

Phase 3 leaders · most advanced

  1. active AbbVie NCT03844048
  2. recruiting The First Affiliated Hospital of Soochow University NCT07583888
  3. recruiting Kura Oncology, Inc. NCT07007312
  4. recruiting University of Ulm NCT04628026
  5. recruiting Servier Affaires Médicales NCT05907057

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 2 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes
Single-program mechanisms (19) — one program each — earliest-stage, sorted by phase
PhaseMechanismCompanyModalityReadoutTrial
Ph3 IDH1 ⚡ 🌱 🆕 Hutchmed 4Q28 NCT06387069
Ph2+Ph3 Radioligand (isotope-labeled) 🌱 🆕 Actinium Cell therapy 1Q29 NCT07157514
Ph3 S1P modulator 🌱 🆕 Priothera SAS 2Q27 NCT05429632
Ph1+Ph2 CD47 / SIRPα 🌱 Akeso 3Q25 NCT04980885
Ph1+Ph2 CDK9 ⚡ 🌱 Sellas Life Sciences Group Oral ⏰ 4Q26 NCT04588922
Ph1+Ph2 Menin inhibitor ⚡ 🌱 AstraZeneca 1Q29 NCT07155226
Ph1+Ph2 NPM1 ⚡ 🌱 🆕 Miltenyi Biomedicine 2Q28 NCT06424340
Ph2 Telomerase reverse transcriptase inhibitor ⚡ 🌱 GCP-Service International… 1Q25 NCT05583552
Ph2 Tyrosine-protein kinase receptor FLT3 inhibitor 🌱 Novartis IV 1Q26 NCT03591510
Ph1 4-HYDROXY-IFOSFAMIDE ⚡ 🌱 CERo Therapeutics Holdings IV ⏰ 4Q26 NCT06834282
Ph1 ARGININE DEIMINASE 🌱 🆕 Polaris Group Oral ⏰ 2Q26 NCT05001828
Ph1 C-MYC ⚡ 🌱 🆕 Hangzhou Weben Pharma Oral ⏰ 2Q26 NCT07014449
Ph1 CD123 CAR-T ⚡ 🌱 🆕 Chongqing Precision 4Q27 NCT06690827
Ph1 CD33 ⚡ 🌱 🆕 Precigen 3Q24 NCT03927261
Ph1 CD33-CLL1 CAR-T ⚡ 🌱 iCell Gene Cell therapy 3Q28 NCT07668557
Ph1 CHEK1 ⚡ 🌱 🆕 PharmaEngine ⏰ 4Q26 NCT05659732
Ph1 DNA METHYLTRANSFERASE ⚡ 🌱 Bio-Path Holdings IT 1Q27 NCT05190471
Ph1 FLT3 CAR-T ⚡ 🌱 🆕 Hemogenyx Cell therapy ⏰ 1Q27 NCT06786533
Ph1 PI3K inhibitor 🌱 🆕 Stelexis IV 3Q27 NCT06533761
Emerging & small-cap sponsors (29) — few programs here — partnering / M&A radar
PhaseMechanismCompanyModalityReadoutTrial
Ph1+Ph2 BCL-2 AB Science Oral ⏰ 3Q26 NCT05211570
Ph1 BCL-2 Aptevo Oral 4Q27 NCT06634394
Ph1+Ph2 🇨🇳 BCL-2 inhibitor BeiGene 1Q28 NCT04771130
Ph1 🇨🇳 DNA (cytosine-5)-methyltransferase 3A inhibitor ⚡ Beijing InnoCare Pharma T… 2Q27 NCT06656494
Ph1 BCL-2 BlossomHill Oral ⏰ 2Q26 NCT06501196
Ph1 CD123 ⚡ Cellectis 4Q24 NCT03190278
Ph2 BCL-2 Changzhou Qianhong Bio-ph… Oral 1Q25 NCT06532058
Ph2 KIT Cogent 3Q25 NCT04996875
Ph1+Ph2 BCL-2 Delta-Fly Pharma Oral 1Q26 NCT06382168
Ph1 DNA (cytosine-5)-methyltransferase 3A inhibitor ⚡ Edgewood Oncology 1Q26 NCT04243785
Ph1+Ph2 BCL-2 Ellipses Pharma Oral 4Q27 NCT04581512
Ph1+Ph2 BCL-2 Faron Oral 1Q27 NCT05428969
Ph1 DNA (cytosine-5)-methyltransferase 3A inhibitor ⚡ Foghorn IV 3Q25 NCT04891757
Ph1+Ph2 KIT Incyte Biosciences Intern… 1Q28 NCT03934372
Ph2+Ph3 BCL-2 Ipsen Oral 2Q31 NCT07623187
Ph2 Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor ⚡ Kissei 3Q30 NCT07604064
Ph2 MENIN Kyowa Kirin 1Q27 NCT07623616
Ph1 CD70 OncoVerity Oral 2Q27 NCT04150887
Ph3 DNA (cytosine-5)-methyltransferase 3A inhibitor ⚡ Otsuka Australia SC 4Q24 NCT05883956
Ph1 CD70 Pfizer Oral 3Q27 NCT04227847
Ph2 BCL-2 Ryvu Oral 1Q26 NCT06191263
Ph1 FLT3 Senti Cell therapy 1Q26 NCT06325748
Ph3 Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor ⚡ Servier Affaires Médicales Oral 4Q27 NCT05907057
Ph1 🇨🇳 BCL-2 inhibitor Sichuan Baili ⏰ 4Q26 NCT05924750
Ph1+Ph2 MENIN Sumitomo Pharma America Oral 2Q27 NCT04988555
Ph1 BCL-2 inhibitor SystImmune ⏰ 4Q26 NCT06714591
Ph1+Ph2 BCL-2 Taiho Oncology Oral 3Q24 NCT04657081
Ph1+Ph2 DNA (cytosine-5)-methyltransferase 3A inhibitor ⚡ Treadwell 1Q26 NCT04730258
Ph1 CD123 ⚡ Vincerx Pharma 2Q25 NCT06034275
Unclassified programs (85) — mechanism not captured yet
PhaseMechanismCompanyModalityReadoutTrial
Ph2+Ph3 Azacitidine, ASTX030 (cedazuridine + azacitidine), Azacitidineunclassified Taiho Oncology, Inc. NCT04256317
Ph2+Ph3 Placebo in combination with Cytarabine Injection, Liposomal Ann…unclassified Moleculin Biotech, Inc. NCT06788756
Ph3 Clifutinib, LoDAC, Azacitidineunclassified Sunshine Lake Pharma Co.,… NCT05586074
Ph2+Ph3 BL-M11D1, Cytarabine, Daunorubicinunclassified Sichuan Baili Pharmaceuti… NCT07255872
Ph3 Orca-T, Standard-of-Careunclassified Orca Biosystems, Inc. NCT05316701
Ph3 Galinpepimut-S, Azacitidine, Venetoclaxunclassified Sellas Life Sciences Group NCT04229979
Ph3 Liposomal cytarabine-daunorubicin for injection, 7+3 (cytarabin…unclassified CSPC Zhongnuo Pharmaceuti… NCT06182592
Ph2 Cusatuzumab, Venetoclax, Azacitidineunclassified OncoVerity, Inc. NCT06384261
Ph2 CC-486unclassified Bristol-Myers Squibb NCT05413018
Ph2 Orca-Tunclassified Orca Biosystems, Inc. NCT07216443
Ph1+Ph2 CTX-712unclassified Chordia Therapeutics, Inc. NCT05732103
Ph1+Ph2 Debio 1562Munclassified Debiopharm International … NCT06969430
Ph1+Ph2 CART84unclassified Gyala Therapeutics NCT07471789
Ph2 Tagraxofusp, Venetoclax, Azacitidineunclassified Stemline Therapeutics, In… NCT06456463
Ph1+Ph2 Gilteritinib, Venetoclax, Azacitidineunclassified Astellas Pharma Global De… NCT05520567
Ph1+Ph2 BN104 monotherapy, BN104 monotherapy, BN104 monotherapy - rp2dunclassified Institut de Recherches In… NCT06052813
Ph1+Ph2 CCS1477, Pomalidomide, Dexamethasoneunclassified CellCentric Ltd. NCT04068597
Ph1+Ph2 ARD103, Cyclophosphamide, Fludarabineunclassified ARCE Therapeutics, Inc. NCT06680752
Ph2 ASTX727unclassified Taiho Oncology, Inc. NCT04093570
Ph1+Ph2 MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 …unclassified Molecular Partners AG NCT05673057
Ph1+Ph2 An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determin…unclassified Advesya SAS NCT06281847
Ph1+Ph2 SOC + BSB-1001 Dose Escalation Cohort, SOC+BSB-1001 Expansion D…unclassified BlueSphere Bio, Inc NCT06704152
Ph1+Ph2 Tuspetinib, Venetoclax Oral Tablet, Azacitidine for Intravenous…unclassified Aptose Biosciences Inc. NCT03850574
Ph1+Ph2 Azacitidine, IMGN632, Venetoclaxunclassified AbbVie NCT04086264
Ph1+Ph2 GB3226unclassified Galecto Biotech AB NCT07084584
Ph1+Ph2 U32 CAR-Tunclassified Shanghai Unicar-Therapy B… NCT07036250
Ph2 RVU120unclassified Ryvu Therapeutics SA NCT06268574
Ph1+Ph2 BG1805unclassified Guangzhou Bio-gene Techno… NCT06118788
Ph1+Ph2 Clifutinib Besylateunclassified Sunshine Lake Pharma Co.,… NCT05133882
Ph2 FCN-338 in Combination With Azacitidine or Chemotherapy in Myel…unclassified Shanghai Fosun Pharmaceut… NCT06858618
Ph1+Ph2 ABD-3001, ABD-3001unclassified Advanced BioDesign NCT05601726
Ph1+Ph2 AK117, Azacitidine, Venetoclaxunclassified Akeso NCT06387420
Ph1+Ph2 TGRX-814unclassified Shenzhen TargetRx Co., Lt… NCT06206174
Ph1+Ph2 Allogeneic T cell progenitors, cultured ex-vivounclassified Smart Immune SAS NCT05768035
Ph1+Ph2 SKLB1028 Dose Escalationunclassified CSPC ZhongQi Pharmaceutic… NCT05445154
Ph1+Ph2 SYHX1903unclassified CSPC ZhongQi Pharmaceutic… NCT05055791
Ph1 QUAIL-100unclassified Laguna Biotherapeutics, I… NCT07573111
Ph1 14C-bleximenib, bleximenibunclassified Janssen Research & Develo… NCT07295951
Ph1 JNJ-89853413unclassified Janssen Research & Develo… NCT06618001
Ph1 GEN3018unclassified Genmab NCT07384715
Ph1 SOC+ BSB-2002, SOC+BSB-2002unclassified BlueSphere Bio, Inc NCT07566585
Ph1 ASTX727unclassified Taiho Oncology, Inc. NCT04953897
Ph1 ASTX727unclassified Taiho Oncology, Inc. NCT04953910
Ph1 GLB-001unclassified GluBio Therapeutics Inc. NCT06146257
Ph1 SOC + TSC-100, SOC + TSC-101unclassified TScan Therapeutics, Inc. NCT05473910
Ph1 Ceramide NanoLiposome (Ceraxa)unclassified Keystone Nano, Inc NCT04716452
Ph1 RPT1Gunclassified Remedy Plan, Inc. NCT07107126
Ph1 CBX-250unclassified Crossbow Therapeutics, In… NCT06994676
Ph1 Ziftomenib, Venetoclax, Azacitidineunclassified Kura Oncology, Inc. NCT05735184
Ph1 AUTX-703unclassified Auron Therapeutics, Inc. NCT06846606
Ph1 OrcaGraft (Orca-Q)unclassified Orca Biosystems, Inc. NCT03802695
Ph1 BMF-500unclassified Biomea Fusion Inc. NCT05918692
Ph1 SNDX-5613, Chemotherapy Regimen, HiDACunclassified Syndax Pharmaceuticals NCT06226571
Ph1 STX-0712unclassified Solu Therapeutics, Inc NCT06950034
Ph1 APL-4098, Azacitidine and APL-4098, Azacitidine and Venetoclax …unclassified Apollo Therapeutics Ltd NCT06372717
Ph1 rebecsinibunclassified Aspera Biomedicines, Inc. NCT07250646
Ph1 BYON4413unclassified Byondis B.V. NCT06359002
Ph1 CLN-049unclassified Cullinan Therapeutics Inc. NCT05143996
Ph1 MGD024unclassified MacroGenics NCT05362773
Ph1 MRX-2843unclassified Meryx, Inc. NCT04872478
Ph1 Pivekimab Sunirineunclassified AbbVie NCT07306832
Ph1 MT-401-OTSunclassified Marker Therapeutics, Inc. NCT06552416
Ph1 KK2845_1, KK2845_2, KK2845_3unclassified Kyowa Kirin Co., Ltd. NCT06812104
Ph1 NMS-03597812unclassified Nerviano Medical Sciences NCT06549790
Ph1 GNC-035unclassified Sichuan Baili Pharmaceuti… NCT05104775
Ph1 HPB-092 tabletunclassified Hangzhou Polymed Biopharm… NCT07137637
Ph1 GLB-001unclassified Hangzhou GluBio Pharmaceu… NCT06378437
Ph1 R-TM123, Allo-RevCAR01-Tunclassified AvenCell Europe GmbH NCT05949125
Ph1 Orca-Tunclassified Orca Biosystems, Inc. NCT04013685
Ph1 REM-422unclassified Remix Therapeutics NCT06297941
Ph1 TRX103unclassified Tr1X, Inc. NCT06462365
Ph1 STI-8591unclassified Zhejiang ACEA Pharmaceuti… NCT05947344
Ph1 zelenirstatunclassified Pacylex Pharmaceuticals NCT06613217
Ph1 XS-04 tabletunclassified NovaOnco Therapeutics Co.… NCT06820268
Ph1 NKX101 - CAR NK cell therapyunclassified Nkarta, Inc. NCT04623944
Ph1 FD-001unclassified Chengdu FenDi Pharmaceuti… NCT06731699
Ph1 TQB3455 tablet+Azacitidine for Injectionunclassified Chia Tai Tianqing Pharmac… NCT06550713
Ph1 Iadademstat, Gilteritinib Oral Tabletunclassified Oryzon Genomics S.A. NCT05546580
Ph1 Nerofeunclassified Immune System Key Ltd NCT04365179
Ph1 TCB008unclassified TC Biopharm NCT06463327
Ph1 NCR300 injectionunclassified Nuwacell Biotechnologies … NCT06441084
Ph1 ETH-155008unclassified Shengke Pharmaceuticals (… NCT05758610
Ph1 BG1805unclassified Guangzhou Bio-gene Techno… NCT06347458
Ph1 NTQ2494 tabletunclassified Nanjing Chia-tai Tianqing… NCT06049667
Ph1 FXS0683unclassified Shanghai Fosun Pharmaceut… NCT07616089
Drugs in this landscape: Azacitidine · Venetoclax (VEN) · Ziftomenib · Venetoclax

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
AbbVie 7 11 8
Taiho Oncology, Inc. 5 0 1
Kura Oncology, Inc. 4 0 0
Orca Biosystems, Inc. 3 0 0
Ryvu Therapeutics SA 3 0 0
Novartis 2 11 9
Astellas 2 10 3
Bristol-Myers Squibb 2 6 1
Daiichi Sankyo 2 4 2
Actinium Pharmaceuticals 2 1 1
Bio-Path Holdings, Inc. 2 1 1
Lomond Therapeutics Holdings, Inc. 2 1 0
Kyowa Kirin Co., Ltd. 2 0 1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 2 0 1
BlueSphere Bio, Inc 2 0 0

All 15 active AML sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2024 (143 registered); 2025 saw 129. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (119 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
91
2017
103
2018
122
2019
108
2020
108
2021
94
2022
113
2023
94
2024
143
2025
129
2026
114

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (9)
153
2017 (11)
276
2018 (15)
106
2019 (7)
326
2020 (7)
316
2021 (10)
78
2022 (12)
188
2023 (10)
211
2024 (7)
198
2025 (13)
240
2026 (18)
307

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT03844048 ACTIVE NOT RECRUITING
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie n=165
NCT07583888 RECRUITING
VABu Conditioning in Elderly AML HSCT
The First Affiliated Hospital of Soochow University n=20
NCT07007312 RECRUITING
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc. n=1,300
NCT07581002 NOT YET RECRUITING
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
AbbVie n=660
NCT04628026 RECRUITING
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm n=650
NCT05907057 RECRUITING
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Servier Affaires Médicales n=245
NCT04293562 RECRUITING
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group n=1,186
NCT03182244 ACTIVE NOT RECRUITING
A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation
Astellas Pharma Inc n=276
NCT04256317 RECRUITING
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Taiho Oncology, Inc. n=316
NCT06788756 RECRUITING
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc. n=312
NCT05183035 RECRUITING
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
PedAL BCU, LLC n=130
NCT05429632 RECRUITING
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Priothera SAS n=366
NCT07539818 NOT YET RECRUITING
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
Institute of Hematology & Blood Diseases Hospital, China n=788
NCT07537257 ENROLLING BY INVITATION
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital n=232
NCT07469046 NOT YET RECRUITING
VAH vs VA in Newly Diagnosed Elderly AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine n=308
NCT06713837 RECRUITING
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS n=339
NCT07223814 RECRUITING
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Stichting Hemato-Oncologie voor Volwassenen Nederland n=875
NCT06744504 RECRUITING
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
Institute of Hematology & Blood Diseases Hospital, China n=300
NCT07407140 NOT YET RECRUITING
VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML
Institute of Hematology & Blood Diseases Hospital, China n=300
NCT07463651 RECRUITING
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
The First Affiliated Hospital of Soochow University n=594
NCT07486479 NOT YET RECRUITING
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University n=204
NCT07478991 NOT YET RECRUITING
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
PETHEMA Foundation n=376
NCT07255872 NOT YET RECRUITING
A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd. n=216
NCT05316701 ACTIVE NOT RECRUITING
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca Biosystems, Inc. n=187
NCT07132684 RECRUITING
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Institute of Hematology & Blood Diseases Hospital, China n=240
NCT07022678 RECRUITING
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Children's Oncology Group n=556
NCT07425808 NOT YET RECRUITING
FLT3-ITD Targeted Therapy in Fit AML Patients
European Organisation for Research and Treatment of Cancer - EORTC n=230
NCT04708054 RECRUITING
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center n=324
NCT03480360 ACTIVE NOT RECRUITING
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center n=21
NCT07407660 NOT YET RECRUITING
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Peking University People's Hospital n=250
NCT07366801 RECRUITING
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=64
NCT03701308 ACTIVE NOT RECRUITING
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
National Cancer Institute (NCI) n=267
NCT05457556 ACTIVE NOT RECRUITING
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group n=435
NCT07264010 NOT YET RECRUITING
Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study
Nanfang Hospital, Southern Medical University n=87
NCT06389292 RECRUITING
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Ascentage Pharma Group Inc. n=486
NCT07232134 RECRUITING
The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=100
NCT03173248 ACTIVE NOT RECRUITING
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
Institut de Recherches Internationales Servier n=146
NCT04229979 ACTIVE NOT RECRUITING
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Sellas Life Sciences Group n=127
NCT07157514 NOT YET RECRUITING
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Actinium Pharmaceuticals n=306
NCT07075016 RECRUITING
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=227
NCT02993523 ACTIVE NOT RECRUITING
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
AbbVie n=443
NCT06387069 RECRUITING
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Hutchmed n=316
NCT06990321 RECRUITING
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Yehui Tan n=68
NCT05994690 RECRUITING
CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients
Princess Maxima Center for Pediatric Oncology n=905
NCT02521493 ACTIVE NOT RECRUITING
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Children's Oncology Group n=280
NCT03897127 ACTIVE NOT RECRUITING
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
University of Ulm n=882
NCT05356169 ACTIVE NOT RECRUITING
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China n=312
NCT03021330 ACTIVE NOT RECRUITING
Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML
Institute of Hematology & Blood Diseases Hospital, China n=1,100
NCT06972641 RECRUITING
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation
Ruijin Hospital n=126
NCT06652438 RECRUITING
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Stichting Hemato-Oncologie voor Volwassenen Nederland n=415
NCT03507842 ENROLLING BY INVITATION
A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.
Asan Medical Center n=380
NCT04314219 RECRUITING
Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients
King Faisal Specialist Hospital & Research Center n=264
NCT05991908 RECRUITING
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine n=222
NCT05674539 ENROLLING BY INVITATION
Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology n=200
NCT06810791 RECRUITING
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Nanfang Hospital, Southern Medical University n=876
NCT06802718 RECRUITING
Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia
Peking University People's Hospital n=96
NCT05153226 ACTIVE NOT RECRUITING
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
DKMS gemeinnützige GmbH n=640
NCT05477589 RECRUITING
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Vastra Gotaland Region n=170
NCT04027309 ACTIVE NOT RECRUITING
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=777
NCT04168502 RECRUITING
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Gruppo Italiano Malattie EMatologiche dell'Adulto n=414
NCT05726110 RECRUITING
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital n=50
NCT05177731 ACTIVE NOT RECRUITING
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
Chen Suning n=188
NCT03839771 ACTIVE NOT RECRUITING
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy
Stichting Hemato-Oncologie voor Volwassenen Nederland n=968
NCT06613035 NOT YET RECRUITING
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China n=126
NCT06475820 ACTIVE NOT RECRUITING
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology n=150
NCT02416388 RECRUITING
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
University Hospital, Angers n=3,100
NCT06297772 NOT YET RECRUITING
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Ruijin Hospital n=220
NCT06418776 RECRUITING
IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML
National Research Center for Hematology, Russia n=198
NCT04173533 ACTIVE NOT RECRUITING
Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT
University of Birmingham n=326
NCT05686538 RECRUITING
Innate Donor Effector Allogeneic Lymphocyte Infusion After Stem Cell Transplantation: the IDEAL Trial
Rigshospitalet, Denmark n=80
NCT05939180 RECRUITING
VA vs DA for Newly Diagnosed Hig-risk AML
The First Affiliated Hospital of Soochow University n=116
NCT06182592 NOT YET RECRUITING
A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. n=120
NCT02665065 ACTIVE NOT RECRUITING
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Actinium Pharmaceuticals n=153
NCT05876832 NOT YET RECRUITING
A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)
Shijiazhuang Yiling Pharmaceutical Co. Ltd n=312
NCT05805098 RECRUITING
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
The First Affiliated Hospital of Soochow University n=60
NCT05404906 RECRUITING
AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission
The First Affiliated Hospital of Soochow University n=124
NCT07623187 NOT YET RECRUITING
A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy
Ipsen n=450
NCT07651176 ENROLLING BY INVITATION
Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
First Affiliated Hospital of Zhejiang University n=267
NCT07651163 ENROLLING BY INVITATION
Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
First Affiliated Hospital of Zhejiang University n=450
NCT01231412 COMPLETED
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center n=174
NCT03258931 COMPLETED
Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Arog Pharmaceuticals, Inc. n=214
NCT03250338 COMPLETED
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
Arog Pharmaceuticals, Inc. n=106
NCT04102020 COMPLETED
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
AbbVie n=112
NCT01366612 TERMINATED
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
Hackensack Meridian Health n=53
NCT02730299 COMPLETED
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd n=125
NCT03594149 COMPLETED
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
Centre Henri Becquerel n=60
NCT01371981 COMPLETED
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI) n=1,645
NCT04161885 TERMINATED
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie n=465
NCT03069352 COMPLETED
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
AbbVie n=211
NCT02752035 COMPLETED
A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy
Astellas Pharma Global Development, Inc. n=183
NCT05054543 TERMINATED
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Apollomics Inc. n=140
NCT03765541 TERMINATED
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
University Hospital, Toulouse n=73
NCT05079230 TERMINATED
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Gilead Sciences n=378
NCT04778397 TERMINATED
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
Gilead Sciences n=258
NCT02997202 COMPLETED
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Astellas Pharma Global Development, Inc. n=356
NCT03092674 COMPLETED
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI) n=76
NCT02085408 COMPLETED
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
ECOG-ACRIN Cancer Research Group n=727
NCT02920008 COMPLETED
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc. n=302
NCT03306264 COMPLETED
Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
Astex Pharmaceuticals, Inc. n=227
NCT03275636 COMPLETED
Haploidentical Donor vs mMUD in Hematological Malignancies
DKMS gemeinnützige GmbH n=98
NCT02668653 COMPLETED
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Daiichi Sankyo n=539
NCT02323022 COMPLETED
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
The First Affiliated Hospital of Soochow University n=618
NCT03616470 TERMINATED
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
GlycoMimetics Incorporated n=388
NCT01751997 COMPLETED
Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors
Byung-Sik Cho n=116
NCT04571645 TERMINATED
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Jazz Pharmaceuticals n=9
NCT03379727 COMPLETED
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Novartis Pharmaceuticals n=301
NCT02013648 COMPLETED
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)
University of Ulm n=204
NCT02473146 COMPLETED
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
Versailles Hospital n=225
NCT02461537 COMPLETED
Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML
DKMS gemeinnützige GmbH n=281
NCT05020665 TERMINATED
Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML
Kronos Bio n=15
NCT04842604 COMPLETED
Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML
Pfizer n=14
NCT03699475 TERMINATED
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
Bellicum Pharmaceuticals n=1
NCT01951885 COMPLETED
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Case Comprehensive Cancer Center n=101
NCT03512197 COMPLETED
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
Novartis Pharmaceuticals n=511
NCT03719534 COMPLETED
Haplo HCT vs Haplo-cord HCT for Patients With AML
The First Affiliated Hospital of Soochow University n=134
NCT05188326 COMPLETED
Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients
Associazione Qol-one n=54
NCT03941964 COMPLETED
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
AbbVie n=60
NCT01191957 COMPLETED
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
Gruppo Italiano Trapianto di Midollo Osseo n=252
NCT00893399 COMPLETED
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation
University of Ulm n=600
NCT04326764 TERMINATED
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Goethe University n=52
NCT03504410 TERMINATED
Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML
Cornerstone Pharmaceuticals n=200
NCT04095858 TERMINATED
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=11
NCT03389724 COMPLETED
Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia
Children's Cancer Hospital Egypt 57357 n=245
NCT04093505 TERMINATED
Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)
University Hospital Heidelberg n=28
NCT01303796 COMPLETED
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
Cyclacel Pharmaceuticals, Inc. n=482
NCT04676243 WITHDRAWN
Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML
University Hospital Heidelberg
NCT02999854 TERMINATED
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Kiadis Pharma n=63
NCT04509622 COMPLETED
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
AbbVie n=14
NCT02927938 TERMINATED
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
Wake Forest University Health Sciences n=18
NCT02566395 COMPLETED
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
Northwell Health n=10
NCT03151408 TERMINATED
An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia
Helsinn Healthcare SA n=406
NCT01597778 COMPLETED
Double Cord Versus Haploidentical (BMT CTN 1101)
Medical College of Wisconsin n=368
NCT00766779 TERMINATED
HCT Versus CT in Elderly AML
European Society for Blood and Marrow Transplantation n=126
NCT02298166 TERMINATED
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
University of Ulm n=9
NCT00703820 COMPLETED
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
St. Jude Children's Research Hospital n=324
NCT03825887 COMPLETED
Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients
Children's Cancer Hospital Egypt 57357 n=80
NCT01817075 COMPLETED
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Children's Oncology Group n=177
NCT03066466 WITHDRAWN
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Loyola University
NCT01307579 COMPLETED
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
Children's Oncology Group n=517
NCT00606723 COMPLETED
Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
Hannover Medical School n=154
NCT02039726 COMPLETED
(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive
Daiichi Sankyo n=367
NCT01371656 COMPLETED
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group n=624
NCT01696084 COMPLETED
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia
Jazz Pharmaceuticals n=309
NCT00822393 COMPLETED
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
medac GmbH n=570
NCT01854567 COMPLETED
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Mesoblast, Ltd. n=49
NCT02319135 COMPLETED
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
PETHEMA Foundation n=289
NCT02870777 COMPLETED
MRD-directed Therapy for Low-risk and Intermediate-risk AML.
Nanfang Hospital, Southern Medical University n=743
NCT02671708 COMPLETED
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University n=153
NCT00952588 COMPLETED
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
AstraZeneca n=74
NCT00887068 COMPLETED
Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
M.D. Anderson Cancer Center n=187
NCT01305200 COMPLETED
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group n=226
NCT02474290 COMPLETED
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
Nanfang Hospital, Southern Medical University n=202
NCT01295710 COMPLETED
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
Neovii Biotech n=260
NCT01802333 COMPLETED
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI) n=754
NCT02785900 TERMINATED
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Seagen Inc. n=240
NCT01191801 COMPLETED
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML
Sunesis Pharmaceuticals n=711
NCT01588951 TERMINATED
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins n=10
NCT01237808 COMPLETED
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
University of Ulm n=144
NCT00656448 COMPLETED
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
M.D. Anderson Cancer Center n=51
NCT01382147 COMPLETED
Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)
Prof. Dr. Wolfgang Hiddemann n=396
NCT01074047 COMPLETED
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
Celgene n=488
NCT01749111 TERMINATED
Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis
Hospital Israelita Albert Einstein n=3
NCT01067274 WITHDRAWN
ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
Acute Leukemia French Association
NCT00909168 COMPLETED
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)
University Hospital, Udine, Italy n=130
NCT00590837 COMPLETED
Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old
University Hospital, Bordeaux n=459
NCT01110824 COMPLETED
Prevention of Left Ventricular Dysfunction During Chemotherapy
Hospital Clinic of Barcelona n=90
NCT01147939 COMPLETED
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Clavis Pharma n=381
NCT00799461 COMPLETED
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium n=1,337
NCT05654194 COMPLETED
Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML
The First Affiliated Hospital of Soochow University n=60

Full AML Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the AML landscape

How many companies are developing Acute Myeloid Leukemia (AML) treatments?
12 companies have active or registered Acute Myeloid Leukemia (AML) programs in TheraRadar's competitive landscape (74 classified trials). The most active are Ascentage Pharma Group, Daiichi Sankyo, and Johnson & Johnson.
What mechanisms of action are being developed for Acute Myeloid Leukemia (AML)?
7 distinct mechanisms of action appear across the Acute Myeloid Leukemia (AML) pipeline, including FLT3, BCL-2, MENIN, BCL-2 inhibitor, and DNA (cytosine-5)-methyltransferase 3A inhibitor.
What is the most crowded mechanism in Acute Myeloid Leukemia (AML)?
FLT3 is the most contested mechanism in Acute Myeloid Leukemia (AML), with 6 programs mapped to it.
Are there upcoming Acute Myeloid Leukemia (AML) clinical readouts or FDA decisions?
Near-term Acute Myeloid Leukemia (AML) catalysts include ZE50-0134 (data readout, Sep '26); Venetoclax (data readout, Feb '27); XY0206 (data readout, Jul '27). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Acute Myeloid Leukemia (AML) landscape data come from?
Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Acute Myeloid Leukemia (AML) heatmap free to use?
Yes — viewing and searching the Acute Myeloid Leukemia (AML) heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

  • In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
  • Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

  1. Healthy-volunteer studies are set aside as non-disease trials.
  2. Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
  3. Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
  4. Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
  5. Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

  1. Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
  2. Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
  3. Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
  4. AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

  • ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
  • ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
  • ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
  • 🌱 First-in-indication — the only program competing on that mechanism within this disease.
  • 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
  • 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

  • Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
  • Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
  • Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

  • Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
  • Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
  • MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
  • Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

  • First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
  • NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
  • Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
  • AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
  • Sponsor names are as-filed and may lag current ownership.
  • Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only